Key points are not available for this paper at this time.
Lay Summary We report that upadacitinib intended for short-term use in combination with biologic therapy appeared to be effective in inducing steroid-free clinical remission in patients with active inflammatory bowel disease, but a substantial proportion of patients required extended use.
Yin et al. (Mon,) studied this question.